Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Regeneron’s antibody cocktail hits target in COVID prevention studyRegeneron is to ask the FDA for clearance to use its antibody cocktail as a preventive treatment for Share XRegeneron’s antibody cocktail hits target in COVID prevention studyhttps://pharmaphorum.com/news/regeneron-to-ask-fda-to-c/
Regeneron’s antibody cocktail cuts COVID hospitalisation in large trialRegeneron has posted findings from a large trial of its COVID-19 antibody cocktail showing the therapy reduced risk Share XRegeneron’s antibody cocktail cuts COVID hospitalisation in large trialhttps://pharmaphorum.com/news/regenerons-antibody-cocktail-cuts-covid-hospitalisation-in-large-trial/
Sanofi, Regeneron prep filings for Libtayo in cervical cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a Share XSanofi, Regeneron prep filings for Libtayo in cervical cancerhttps://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/
ExeVir ready for clinic with variant-targeting llama antibodyLast year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – Share XExeVir ready for clinic with variant-targeting llama antibodyhttps://pharmaphorum.com/news/exevirs-ready-for-clinic-with-covid-variant-busting-llama-antibody/
EMA backs emergency use of Lilly’s COVID antibodiesThe EMA’s human medicines committee has said two Eli Lilly antibodies are effective in people with COVID-19 who Share XEMA backs emergency use of Lilly’s COVID antibodieshttps://pharmaphorum.com/news/ema-backs-emergency-use-of-lillys-covid-antibodies/
Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
FDA grants emergency licence for Lilly’s COVID-19 antibody comboThe FDA has granted an emergency licence for Eli Lilly’s COVID-19 antibody combination therapy, to reduce chances of Share XFDA grants emergency licence for Lilly’s COVID-19 antibody combohttps://pharmaphorum.com/news/fda-grants-emergency-licence-for-covid-19-antibody-combination/
UK patient group warns COVID could limit access to Novartis’ new eye drugNICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – Share XUK patient group warns COVID could limit access to Novartis’ new eye drughttps://pharmaphorum.com/news/patient-group-warns-covid-limit-access-novartis-eye-drug/
